Quantcast

Latest Choroidal neovascularization Stories

2014-06-27 08:24:46

TARRYTOWN, N.Y., June 27, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA(®) (aflibercept) Injection has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of visual impairment due to diabetic macular edema (DME). The decision of the European Commission is expected in the second half of 2014. "Diabetes is a growing health concern worldwide and this milestone brings us...

2014-06-19 08:28:14

SOPHIA ANTIPOLIS, France, and SAN DIEGO, June 19, 2014 /PRNewswire/ -- Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, and Sequenom, Inc. (NASDAQ:SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that Nicox's subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories' RetnaGene(TM) portfolio of laboratory-developed genetic tests in the United States (U.S.). The RetnaGene portfolio includes...

2014-02-10 08:26:04

TARRYTOWN, N.Y., Feb. 10, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that in the Phase 3 VISTA-DME trial of EYLEA(®) (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100, compared to...

2014-01-16 20:22:14

Nicox further expands North American diagnostic portfolio with access to the RetnaGene AMD test, a genetic laboratory-developed test to predict the risk of progressing to late-stage or "wet" age-related macular degeneration (AMD) SOPHIA ANTIPOLIS, France and SAN DIEGO, Jan. 16, 2014 /PRNewswire/ -- Nicox S.A. (NYSE Euronext Paris: COX), and Sequenom, Inc. (NASDAQ:SQNM), today announced that their affiliate companies (Nicox Inc. and Sequenom Laboratories) have entered into an...

2013-10-30 23:26:30

Bel Marra Health, who offers high-quality, specially formulated vitamins and nutritional supplements, reports on a recent study revealing a new topical treatment to treat vision loss caused by macular generation. Toronto, ON (PRWEB) October 30, 2013 Bel Marra Health, who offers high-quality, specially formulated vitamins and nutritional supplements, reports on a recent study revealing a new topical treatment to treat vision loss caused by macular generation. As Bel Marra Health reports in...

2013-08-19 15:30:13

Time-release coating allows drug for macular degeneration to last longer Johns Hopkins biomedical engineers have teamed up with clinicians to create a new drug-delivery strategy for a type of central vision loss caused by blood vessel growth at the back of the eye, where such growth should not occur. In addition to testing a new drug that effectively stops such runaway vessel growth in mice, the team gave the drug a biodegradable coating to keep it in the eye longer. If proven effective...

Promising Results From Pilot Study For AMD
2013-06-18 13:40:01

University of Iowa There is no cure for age-related macular degeneration, an eye disease that is the leading cause of vision loss and blindness in older Americans. Last year, the National Institutes of Health reported that two drugs injected into the eyes, Avastin and Lucentis, eased symptoms for sufferers, especially those in the advanced, “wet” stage of the disease, when blood vessels in the eye become swollen and leak fluids in the eye. Yet for some AMD patients, the two...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.